Tender

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

Onasemnogene Abeparvovec Intravenous (Zolgensma(r)) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

NHS England

This public procurement record has 1 release in its history.

Tender

04 Jun 2026 at 16:37

Tender Notice
Summary of the contracting process

NHS England has initiated a tender process for the provision of gene replacement therapy services focused on spinal muscular atrophy (SMA), titled "Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service". This procurement falls under the health services category (CPV 85100000) and covers the UK region. The process has been structured into lots, allowing bidders to apply based on their capability, with a submission deadline set for 8 July 2026. The procurement is currently in the tender stage, following an open procedure, and seeks to serve the population under NHS England, with potential contract durations extending up to five years.

This tender offers significant opportunities for businesses operating within the healthcare services industry, particularly those specialising in gene therapy and rare genetic disorders. Suppliers capable of providing innovative solutions and tailored therapeutic services for SMA are well-suited to compete. Engaging in this procurement process can enable companies to expand their influence in the health sector, leveraging cutting-edge medical therapies to deliver impactful patient outcomes. By strategically aligning with NHS England's objectives, businesses can enhance their portfolio and contribute to advancing healthcare services for those affected by SMA.

How relevant is this notice?

Notice Information

Notice Title

Onasemnogene Abeparvovec Intravenous (Zolgensma(r)) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

Notice Description

Onasemnogene abeparvovec intravenous (Zolgensma(r)) is a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.<br/><br/>Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE's technology appraisal programme, with an expected final guidance publication date in late 2026.

Lot Information

Lot 1

Lot 1: Zolgensma only (if no positive NICE recommendation for OAV101 IT)

Options: Contract period for 3 years with the option to extend up to 2 additional years

Renewal: Commissioners may decide to to renew the contract at the end of its term

Lot 2

Lot 2: Positive recommendation for OAV101 IT for paediatric patients (in combination with Lot 1 for Zolgensma)

Options: Contract period for 3 years with the option to extend up to a further 2 years

Renewal: Commissioners may decide to to renew the contract at the end of its term

Lots 3

Lot 3: Positive NICE recommendation for OAV101 IT for adult patients (either standalone or in combination with Lots 1 and 2)

Options: Contract period for 3 years with the option to extend up to a further 2 years

Renewal: Commissioners may decide to to renew the contract at the end of its term

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-06ae08
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/053026-2026
Current Stage
Tender
All Stages
Tender

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Standard
Procurement Category
Services
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions

85 - Health and social work services

CPV Codes

85100000 - Health services

Notice Value(s)

Tender Value
£26,136,000 £10M-£100M
Lots Value
£26,136,000 £10M-£100M
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
4 Jun 20262 months ago
Submission Deadline
8 Jul 2026Expired
Future Notice Date
Not specified
Award Date
Not specified
Contract Period
Not specified - Not specified
Recurrence
Not specified

Notice Status

Tender Status
Active
Lots Status
Active
Awards Status
Not Specified
Contracts Status
Not Specified

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SE1 8UG
Postcode Area
South East London
Country
England
Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI4 Inner London - East
Small Region (ITL 3)
TLI45 Lambeth
Delivery Location
Not specified
Local Authority
Lambeth
Electoral Ward
Waterloo & South Bank
Westminster Constituency
Vauxhall and Camberwell Green

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...